After failing to outperform chemoradiation in muscle-invasive disease, TAR-200 may be repositioned. Instead of a primary treatment, it could be used sequentially after an effective systemic therapy to control the high-grade, non-muscle invasive relapses that often occur in patients who achieve a major response and wish to preserve their bladder.

Kaplan-Meier curves from the VICTORIA-1 trial show a steep, immediate drop-off for patients on fulvestrant monotherapy, with ~60% progressing quickly. In contrast, the giredestrant combination arms show a much flatter initial curve, visually demonstrating that a primary benefit is protecting the large subset of patients who would otherwise fail therapy very early.

An FDA analysis showed the survival curve for kidney cancer patients on IO-IO therapy (ipinevo) is much flatter for those with early tumor growth compared to IO-TKI regimens. This suggests early progression on a dual-mechanism IO-TKI therapy indicates true resistance, while on IO-IO it could be delayed response.

In the SUNRISE 2 trial, 44% of patients had no detectable tumor after pre-treatment resection. This high baseline inflates the final clinical complete response (CR) rates (e.g., 59% in the control arm), making CR a misleading indicator of the actual therapeutic benefit, which was a much smaller improvement over baseline.

The SUNRISE 2 trial's chemoradiation arm showed unexpectedly strong results. This is likely due to a protocol requiring a repeat resection (RIT-URBT) before randomization, which weeded out aggressive tumors and selected a patient population with a better prognosis, making the control arm unusually difficult to beat.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.

The TRILINX trial found that adding Xevinapant to local chemoradiation did not improve local control but was associated with a higher rate of distant cancer failures. This counterintuitive outcome highlights the risk of unintended, detrimental systemic effects when developing combination therapies for localized disease.

The control arm relapse rate in the SUNRISE 2 trial was only ~20%, while in the EV-303/KEYNOTE-905 trial it was ~60%. This huge discrepancy highlights that current clinical staging and selection criteria are poor at identifying patient risk, signaling an urgent need for better stratification tools like ctDNA for more effective clinical trials.